Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IMGT® analysis of the human IGH locus: unveiling novel polymorphisms and copy number variations in 15 genome assemblies from diverse ancestral backgrounds. | NAR Genom Bioinform | 2025 | 40977881 | PubTator, text mining | PubMed |
| Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study. | Leukemia | 2025 | 40973766 | PubTator, text mining | PubMed |
| Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013-2022 in Finland. | Ann Hematol | 2025 | 40970924 | PubTator, text mining | PubMed |
| Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies. | Int J Mol Sci | 2025 | 40943662 | PubTator, text mining | PubMed |
| Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras. | Blood Adv | 2025 | 40902084 | PubTator, text mining | PubMed |
| Persistent Immune Dysregulation during Post-Acute Sequelae of COVID-19 is Manifested in Antibodies Targeting Envelope and Nucleocapsid Proteins. | bioRxiv | 2025 | 40894595 | PubTator, text mining | PubMed |
| MYC target gene activation in chronic lymphocytic leukemia and richter transformation: links to aggressiveness and tumor microenvironment interactions. | Front Pharmacol | 2025 | 40894230 | PubTator, text mining | PubMed |
| Mutational signature analysis of chronic lymphocytic leukemia uncovering genomic patterns and prognostic implications. | Am J Clin Pathol | 2025 | 40814292 | PubTator, text mining | PubMed |
| C to U RNA editing of MFN1 is regulated by ADARB1 and associates with favourable prognosis in chronic lymphocytic leukemia. | Sci Rep | 2025 | 40813454 | PubTator, text mining | PubMed |
| A Sitewise Model of Natural Selection on Individual Antibodies via a Transformer-Encoder. | Mol Biol Evol | 2025 | 40794593 | PubTator, text mining | PubMed |
| Genotyping of selected germline adaptive immune system loci using short-read sequencing data. | Genome Res | 2025 | 40764056 | PubTator, text mining | PubMed |
| Isolation of genetically diverse influenza antibodies highlights the role of IG germline gene variation and informs the design of population-comprehensive vaccine strategies. | bioRxiv | 2025 | 40747420 | PubTator, text mining | PubMed |
| Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. | Blood | 2025 | 40737596 | PubTator, text mining | PubMed |
| Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS). | Ann Hematol | 2025 | 40736551 | PubTator, text mining | PubMed |
| Methylation-based droplet digital polymerase chain reaction shows high concordance with chronic lymphocytic leukemia IGHV somatic mutation status. | Am J Clin Pathol | 2025 | 40734655 | PubTator, text mining | PubMed |
| Precision Medicine in Hematologic Malignancies: Evolving Concepts and Clinical Applications. | Biomedicines | 2025 | 40722725 | PubTator, text mining | PubMed |
| Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment. | Curr Treat Options Oncol | 2025 | 40679679 | PubTator, text mining | PubMed |
| Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States. | Oncologist | 2025 | 40581075 | PubTator, text mining | PubMed |
| Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes. | Leukemia | 2025 | 40562789 | PubTator, text mining | PubMed |
| One for the ages: impact of age on international prognostic indices in lymphoid cancer. | Blood Adv | 2025 | 40540808 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=6